Charles River Laboratories Other Non-Cash Items 2010-2025 | CRL

Charles River Laboratories annual/quarterly other non-cash items history and growth rate from 2010 to 2025. Other non-cash items can be defined as miscellaneous non-cash adjustments to Net income.
  • Charles River Laboratories other non-cash items for the quarter ending March 31, 2025 were $0.020B, a 9.93% increase year-over-year.
  • Charles River Laboratories other non-cash items for the twelve months ending March 31, 2025 were $0.228B, a 89.37% increase year-over-year.
  • Charles River Laboratories annual other non-cash items for 2024 were $0.13B, a 1494.55% decline from 2023.
  • Charles River Laboratories annual other non-cash items for 2023 were $-0.009B, a 76.99% decline from 2022.
  • Charles River Laboratories annual other non-cash items for 2022 were $-0.04B, a 179.35% decline from 2021.
Charles River Laboratories Annual Other Non-Cash Items
(Millions of US $)
2024 $130
2023 $-9
2022 $-40
2021 $51
2020 $-35
2019 $20
2018 $20
2017 $56
2016 $42
2015 $30
2014 $31
2013 $24
2012 $32
2011 $25
2010 $83
2009 $42
Sector Industry Market Cap Revenue
Medical Medical Services $7.445B $4.050B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $144.179B 27.04
CVS Health (CVS) United States $86.198B 10.71
Elevance Health (ELV) United States $84.314B 10.88
Cencora (COR) United States $57.484B 20.00
DiDi Global (DIDIY) China $23.485B 24.95
Natera (NTRA) United States $22.963B 0.00
Labcorp Holdings (LH) United States $21.509B 17.45
BioMerieux (BMXMF) France $16.861B 0.00
EUROFINS SCIENT (ERFSF) Luxembourg $14.205B 0.00
Solventum (SOLV) United States $12.912B 13.67
CochLear (CHEOY) Australia $12.870B 0.00
ICON (ICLR) Ireland $11.851B 11.02
Revvity (RVTY) United States $11.644B 20.04
Viatris (VTRS) United States $10.704B 3.68
Avantor (AVTR) United States $9.363B 13.60
HealthEquity (HQY) United States $9.068B 39.72
Medpace Holdings (MEDP) United States $8.818B 23.42
Sonic Healthcare (SKHHY) Australia $8.465B 0.00
Amplifon S.p.A (AMFPF) Italy $5.378B 29.44
Bausch + Lomb (BLCO) Canada $4.269B 25.15
BrightSpring Health Services (BTSG) United States $4.058B 37.23
Sotera Health (SHC) United States $3.225B 18.32
Surgery Partners (SGRY) United States $2.781B 36.17
Alignment Healthcare (ALHC) United States $2.722B 0.00
Concentras Parent (CON) United States $2.652B 15.33
Organon (OGN) United States $2.594B 2.76
GeneDx Holdings (WGS) United States $2.556B 98.45
PACS (PACS) United States $1.958B 0.00
Ardent Health (ARDT) United States $1.904B 8.12
Progyny (PGNY) United States $1.840B 40.49
Premier (PINC) United States $1.796B 13.63
GoodRx Holdings (GDRX) United States $1.761B 35.21
Teladoc Health (TDOC) United States $1.412B 0.00
Establishment Labs Holdings (ESTA) $1.181B 0.00
Pediatrix Medical (MD) United States $1.171B 8.91
CareDx (CDNA) United States $1.074B 16.77
Agilon Health (AGL) United States $0.956B 0.00
Ryman Healthcare (RYHTY) New Zealand $0.919B 0.00
QDM (QDMI) Hong Kong, SAR China $0.840B 0.00
AMN Healthcare Services Inc (AMN) United States $0.806B 7.54
Nutex Health (NUTX) United States $0.658B 9.96
LifeMD (LFMD) United States $0.615B 0.00
Embecta (EMBC) United States $0.542B 3.65
InnovAge Holding (INNV) United States $0.532B 0.00
Enhabit (EHAB) United States $0.482B 39.62
Auna S.A (AUNA) Luxembourg $0.470B 10.58
SBC Medicals (SBC) United States $0.464B 0.00
Omada Health (OMDA) $0.460B 0.00
Sonida Senior Living (SNDA) United States $0.459B 0.00
Performant Healthcare (PHLT) United States $0.312B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.249B 0.00
Beauty Health (SKIN) United States $0.244B 0.00
So-Young (SY) China $0.209B 0.00
Oncology Institute (TOI) United States $0.200B 0.00
DocGo (DCGO) United States $0.172B 28.17
Pheton Holdings (PTHL) China $0.115B 0.00
Insight Molecular Diagnostics (IMDX) United States $0.096B 0.00
KindlyMD (NAKA) United States $0.089B 0.00
Sera Prognostics (SERA) United States $0.075B 0.00
Ascend Wellness Holdings (AAWH) United States $0.063B 0.00
NeueHealth (NEUE) United States $0.061B 0.00
IceCure Medical (ICCM) Israel $0.056B 0.00
ModivCare (MODV) United States $0.051B 0.00
Biodesix (BDSX) United States $0.041B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.036B 0.00
Basel Medical Group (BMGL) Singapore $0.033B 0.00
Intelligent Bio Solutions (INBS) United States $0.012B 0.00
Co-Diagnostics (CODX) United States $0.009B 0.00
XWELL (XWEL) United States $0.005B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
SeaStar Medical Holding (ICU) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
ISpecimen (ISPC) United States $0.002B 0.00
INVO Fertility (IVF) United States $0.002B 0.00
NewGenIvf Group (NIVF) Thailand $0.001B 0.00
Cano Health (CANOQ) United States $0.000B 0.00